SCHEMBL5373442

SCHEMBL5373442

CCCCOc1ccc(CSc2ccc(N)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 3/20 0.52
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
TSHR P16473 2/20 0.50
HTT P42858 1/20 0.50
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
APP P05067 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LTA4H P09960 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10525967 0.82 NPC1 (0.51) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL177701 0.82 TSHR (0.53) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL112238 0.81 TSHR (0.67) NPC1RAB9AKMT2AALDH1A1LMNA
SCHEMBL10528251 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10527573 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10534156 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10528428 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10530313 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL10527645 0.81 NPC1 (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL28070732 0.80 APP (0.70) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
CN-1930121-A Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER PROD INC (US) 2007-03-14 CN disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD NPC1 59/4885RAB9A 2271/4885MEN1 4855/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD NPC1 74/4885RAB9A 2063/4885MEN1 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.